Endocrinology Advisor2d
Primary Aldosteronism Treatment Could Improve With PAMO Criteria
Primary aldosteronism treatment response was associated with higher plasma renin activity and serum potassium levels and lower aldosterone.
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
Travere Therapeutics, Inc.: Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...